Included in the formulation
АТХ:A.10.B.X.07 Liraglutide
Pharmacodynamics:The analogue of human glucagon-like peptide-1, stimulates glucose-dependent insulin secretion in β-cells of the pancreas. Competitively suppresses excessive glucose-dependent secretion of glucagon. When hypoglycemia reduces the secretion of insulin, without affecting the production of glucagon. Minor delays gastric emptying, reduces energy consumption, thereby reducing the amount of fat tissue and hunger.
Pharmacokinetics:After subcutaneous administration, the bioavailability is about 55%. The maximum concentration in the blood plasma is reached in 8-12 hours. The connection with plasma proteins is more than 98%.
Metabolism in the liver.
The half-life is 13 hours. Elimination by the kidneys.
Indications:It is used for the treatment of diabetes mellitus II type in combination with oral hypoglycemic agents
IV.E10-E14.E11 Non-insulin-dependent diabetes mellitus
Contraindications:Diabetes I type, severe cardiac, hepatic and renal insufficiency, diabetic ketoacidosis, paresis of the stomach, inflammatory bowel disease, individual intolerance.
Carefully:Cardiac, renal and hepatic insufficiency of mild and moderate severity, hypersensitivity, age over 75 years.
Pregnancy and lactation:Recommendations for FDA - Category C. Contraindicated in pregnancy and lactation.
Dosing and Administration:Subcutaneously once a day, preferably at the same time. The dose is calculated individually according to the level of glucose in the blood plasma. The initial dose is 0.6 mg, if necessary, after one week the dose is doubled, to 1.2 mg.
The highest daily dose: 1.8 mg.
The highest single dose: 1.8 mg.
Side effects:Digestive system: anorexia, decreased appetite, hypoglycemia - when combined with sulfonylureas, nausea, diarrhea, belching, bloating, gastroesophageal reflux.
Allergic reactions.
Overdose:Nausea and vomiting.
Treatment is symptomatic.
Interaction:It is combined with insulin and oral hypoglycemic agents.
Special instructions:When treated in combination with oral hypoglycemic agents are not recommended driving vehicles and working with moving mechanisms (in connection with the possible risk of hypoglycemia).